The global continuous renal replacement therapy market was valued at USD 1.4 billion in 2021 and it is anticipated to grow at a CAGR 6.3% during the forecast period to reach up to USD 2.6 billion by 2031.
Continuous renal replacement therapy (CRRT) is a popular choice of therapy usually used for renal support in critically ill patients with acute kidney injury (AKI), primarily in hemodynamically unstable patients. It comprises the solute removal from the blood through the process of hemodialysis or hemofiltration or a combination of both methods. The CRRT therapy is generally carried out for about 24 hours in an ICU, making it altered from other kinds of conventional renal replacement therapies such as intermittent hemodialysis (IHD) which lasts for about 4 to 6 hours or even less.